COPD and Asthma Devices Market Size, Share, Growth Analysis, By Product Type(Chronic Obstructive Pulmonary Disease (COPD) and Asthma), By Indication(Retail Pharmacies, Hospitals and Online Pharmacies), By Region - Industry Forecast 2024-2031

COPD and Asthma Devices Market Driver

Growing Prevalence of Different Respiratory Conditions

• The prevalence of respiratory conditions including COPD, asthma, and emphysema is on the rise. Additionally, there is a growing need for short-term, effective treatment as well as a growing requirement for rescue medication during abrupt asthmatic attacks. Additionally, the government's measures to raise awareness of the signs of COPD and asthma, as well as manufacturers' increased focus on the development of innovative, portable inhalation devices, are anticipated to spur market expansion.
• The Asthma and COPD Devices Market is expanding as a result of rising respiratory illness rates. Respiratory illnesses cause troubling symptoms, potentially fatal disorders, and other health issues. Chronic obstructive pulmonary disease (COPD) is brought on by lung inflammation and destruction. This causes the irritated airways to spasm and enlarge while producing too much mucus. In an attack, those with respiratory illnesses cough and have trouble breathing.
• The market for asthma and COPD devices is expanding along with the evolution of technology. This is due to the rising prevalence of respiratory disorders and the improvements in advanced portable inhalation technologies. The most cutting-edge method of medicine delivery for respiratory ailments is through asthma and COPD devices, which may be employed as a temporary fix or a long-term cure.

COPD and Asthma Devices Market Restraint

High Cost to Hamper Market Growth

• The market growth is anticipated to be constrained by elements like environmental issues related to metered dosage inhalers (MDI), high costs of various inhalation devices and treatments, increased price competition, and deteriorating material quality. Additionally, poor reimbursement support and the patent expiry of blockbuster medications hinder market expansion.